NO162234C - Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinkarboksylsyreestere. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinkarboksylsyreestere.

Info

Publication number
NO162234C
NO162234C NO830539A NO830539A NO162234C NO 162234 C NO162234 C NO 162234C NO 830539 A NO830539 A NO 830539A NO 830539 A NO830539 A NO 830539A NO 162234 C NO162234 C NO 162234C
Authority
NO
Norway
Prior art keywords
acid esters
preparation
carboxyl acid
therapeutic active
active pyridine
Prior art date
Application number
NO830539A
Other languages
English (en)
Norwegian (no)
Other versions
NO162234B (no
NO830539L (no
Inventor
Egbert Wehinger
Horst Meyer
Ulrich Benz
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO830539L publication Critical patent/NO830539L/no
Publication of NO162234B publication Critical patent/NO162234B/no
Publication of NO162234C publication Critical patent/NO162234C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
  • Drawers Of Furniture (AREA)
NO830539A 1982-03-13 1983-02-17 Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinkarboksylsyreestere. NO162234C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823209274 DE3209274A1 (de) 1982-03-13 1982-03-13 Pyridincarbonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
NO830539L NO830539L (no) 1983-09-14
NO162234B NO162234B (no) 1989-08-21
NO162234C true NO162234C (no) 1989-11-29

Family

ID=6158229

Family Applications (1)

Application Number Title Priority Date Filing Date
NO830539A NO162234C (no) 1982-03-13 1983-02-17 Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinkarboksylsyreestere.

Country Status (18)

Country Link
US (1) US4705794A (da)
EP (1) EP0088940B1 (da)
JP (1) JPS58167571A (da)
KR (1) KR910000637B1 (da)
AT (1) ATE19875T1 (da)
AU (1) AU564367B2 (da)
CA (1) CA1208216A (da)
DE (2) DE3209274A1 (da)
DK (1) DK157857C (da)
FI (1) FI82687C (da)
GR (1) GR78454B (da)
HU (1) HU188851B (da)
IE (1) IE54879B1 (da)
IL (1) IL68095A (da)
NO (1) NO162234C (da)
PH (1) PH19685A (da)
PT (1) PT76328B (da)
ZA (1) ZA831691B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58185821U (ja) * 1982-06-02 1983-12-10 日産自動車株式会社 ウインドシ−ルド
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
DE3410645A1 (de) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB8530602D0 (en) * 1985-12-12 1986-01-22 Fujisawa Pharmaceutical Co Heterocyclic compounds
IT1204948B (it) * 1987-03-13 1989-03-10 Boheringer Biochemia Robin S P 2-tiometil-sostituite-piridine, metodo per la loro preparazione e composizioni farmaceutiche che le contengono.
DE3712371A1 (de) * 1987-04-11 1988-10-27 Bayer Ag Substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung
DE3712369A1 (de) * 1987-04-11 1988-10-27 Bayer Ag Substituierte 5-nitro-1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung
US4843085A (en) * 1987-07-01 1989-06-27 Yamanouchi Pharmaceutical Co., Ltd. Pyridine derivatives, process for production thereof and pharmaceutical compositions useful as anti-arhytmics
US5100892A (en) * 1990-11-13 1992-03-31 Glaxo Inc. Dihydropyridine vasodilator agents
RU2124502C1 (ru) * 1993-11-23 1999-01-10 Акционерное общество закрытого типа "Фармакор" ПРОИЗВОДНЫЕ β- ГИДРОКСИЭТИЛАМИНИЙНИКОТИНАТА, ПРОЯВЛЯЮЩИЕ ПРОТИВОИШЕМИЧЕСКУЮ АКТИВНОСТЬ
EP0657432B1 (de) * 1993-12-10 2003-03-12 Bayer Ag Phenyl-substituierte 1,4-Dihydropyridine mit cerebraler Aktivität
DE4430638A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
DE4430639A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
AU2004272078A1 (en) * 2003-09-10 2005-03-24 Synta Pharmaceuticals Corp. Dihydropyridine compounds for treating or preventing metabolic disorders
RU2245329C1 (ru) * 2003-09-10 2005-01-27 ГУП "Всероссийский научный центр по безопасности биологически активных веществ" (ГУП "ВНЦ БАВ") Гамма-гидроксипропиламиний-5-гидроксиникотинат, обладающий противоишемической, антиаритмической и гиполипидемической активностью

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3209276A1 (de) * 1982-03-13 1983-09-15 Bayer Ag, 5090 Leverkusen Arzneimittel mit antihypoxischer und ischaemie-protektiver wirkung

Also Published As

Publication number Publication date
DK117783D0 (da) 1983-03-11
CA1208216A (en) 1986-07-22
PT76328B (en) 1985-11-11
GR78454B (da) 1984-09-27
NO162234B (no) 1989-08-21
IE830535L (en) 1983-09-13
ZA831691B (en) 1983-12-28
DK117783A (da) 1983-09-14
HU188851B (en) 1986-05-28
JPS58167571A (ja) 1983-10-03
EP0088940A1 (de) 1983-09-21
DK157857C (da) 1990-07-30
IL68095A (en) 1986-12-31
ATE19875T1 (de) 1986-06-15
DE3363581D1 (en) 1986-06-26
AU564367B2 (en) 1987-08-13
FI82687B (fi) 1990-12-31
EP0088940B1 (de) 1986-05-21
JPH0551581B2 (da) 1993-08-03
FI82687C (fi) 1991-04-10
KR840004079A (ko) 1984-10-06
KR910000637B1 (ko) 1991-01-31
DK157857B (da) 1990-02-26
PH19685A (en) 1986-06-13
DE3209274A1 (de) 1983-09-15
PT76328A (en) 1983-04-01
AU1208183A (en) 1983-09-15
US4705794A (en) 1987-11-10
FI830810L (fi) 1983-09-14
FI830810A0 (fi) 1983-03-10
NO830539L (no) 1983-09-14
IE54879B1 (en) 1990-03-14

Similar Documents

Publication Publication Date Title
NO830539L (no) Pyridinkarboksylsyreestere, fremgangsmaate til deres fremstilling samt deres anvendelse som legemiddel
ES2108855T3 (es) Derivados de acido oxamico como agentes hipocolesteremicos.
DK114783A (da) Hidtil ukendte forbindelser, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
FI831604L (fi) Pyridinderivat, deras framstaellning och anvaendning
SE7607566L (sv) Forfarande for framstellning av 1,4-dihydropyridinderivat
DK57492D0 (da) Farmaceutiske praeparater af n-phenylbenzamidderivater
DK0641325T3 (da) Inhibitorer af retroviral protease
DE3852565D1 (de) Aryl-heteroaryl-karbinol-Derivate mit analgetischer Aktivität.
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
DK159148C (da) Analogifremgangsmaade til fremstilling af tranexamsyrederivater
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
SE8204893D0 (sv) Sett att framstella nya oximderivat av 7-amino-tiazolyl-acetamido-cefalosporansyra
DK359387D0 (da) Oploesninger af oxazaphosphoriner med forbedret stabilitet og fremgangsmaade til deres fremstilling
ES520526A0 (es) Procedimiento para la obtencion de derivados de piridina.
NO164978C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heteroaryloxy-beta-carbolinderivater.
DK0539805T3 (da) Phthalaziner indeholdende en ethergruppe i 1-stilling og fremgangsmåde til fremstilling deraf
FI823278L (fi) Foerfarande foer framstaellning av nya triazolokinazoloner och deras salter
ES8100282A1 (es) Procedimiento para la obtencion de nuevos derivados de la piperacina metanimina
NO165106C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-aminoalkyl-beta-carbolinderivater.
NO930844L (no) 2-(2-substituerte pyrrolidinyltio)karbapenem-derivater
NO152252C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme derivater av 4-(n-(substituert-benzyliden)aminometyl)-cykloheksan-1-karboksylsyre
SE8801907D0 (sv) Novel pharmacological compounds
DE2963724D1 (en) Clavulanic acid derivatives, their preparation and pharmaceutical compositions containing them
MX9706187A (es) Derivados de 3-pirrolidiliden-2-ona-cefalosporinas.